Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 30.14
+2.16 (7.72%)
Sep 30, 2026, 4:08 PM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 10.6 billion as of September 29, 2026. Its market cap has decreased by -46.19% in one year.
Market Cap
10.60B
Enterprise Value
10.54B
Revenue
2.78B
Ranking
n/a
PE Ratio
n/a
Stock Price
30.14
ChartMarket Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 10.60B, a decrease of -48.66%. That is a compound annual growth rate of -10.55%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 30, 2026 | 10.60B | -18.89% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| HBM Holdings | 11.38B |
| GenFleet Therapeutics (Shanghai) | 11.07B |
| Ascentage Pharma Group International | 10.63B |
| Nanjing Leads Biolabs | 10.20B |
| Ascletis Pharma | 9.04B |
| Suzhou Ribo Life Science | 8.72B |
| CStone Pharmaceuticals | 8.50B |
| LongBio Pharma (Suzhou) | 8.42B |